Developing high-quality medicine is a resource-intense endeavor that requires collaboration across Novo Nordisk. Novo Nordisk aimed to scale a pipeline of drug discovery, development, and data science capabilities with AI and machine learning. In partnership with Microsoft Research, the teams built a Novo Nordisk AI platform on Azure AI and data stacks. Novo Nordisk amplified its culture of innovation by leveraging Microsoft Azure platform's AI capabilities across many use cases. The teams recently published initial results with predictive AI models for advanced risk detection in cardiovascular diseases, including an algorithm that can predict patients' cardiovascular risk better than the best clinical standards. Read this case study for lessons learned.
How is Novo Nordisk using AI in drug discovery?
Novo Nordisk is leveraging AI and machine learning to enhance its drug discovery and development processes. By building a Novo Nordisk AI platform on Microsoft Azure, the company is able to scale its capabilities and improve collaboration among life scientists, computational biologists, and data scientists. This platform supports various use cases, including predictive AI models for advanced risk detection in cardiovascular diseases.
What are the initial results of AI implementation at Novo Nordisk?
Novo Nordisk has reported promising initial results from its AI initiatives, particularly in cardiovascular disease risk detection. An algorithm developed through this effort can predict patients' cardiovascular risk more accurately than existing clinical standards. This demonstrates the potential of using AI to enhance precision medicine and improve treatment outcomes.
How does collaboration with Microsoft enhance Novo Nordisk's capabilities?
The collaboration between Novo Nordisk and Microsoft Research combines industry expertise in life sciences and applied AI, enabling the development of innovative solutions across various research areas. This partnership facilitates the creation of a unified AI platform that allows for better data discovery, reasoning, and model governance, ultimately supporting the company's goal of pioneering new medicines.
Sign in with LinkedIn